601607 Shanghai Pharmaceuticals Holding
- 19.32
- -0.31-1.58%
Shanghai Pharmaceuticals Holding News
Shanghai Pharmaceutical: Shanghai Pharmaceutical Group Co., Ltd.'s 2021 A-share equity allocation implementation announcement
Shanghai Pharmaceutical: Announcement of the 2021 Annual Profit Distribution Plan of Shanghai Pharmaceutical Group Co., Ltd.
Shanghai Pharmaceutical: Announcement on the results of issuing the fourth instalment of ultra-short-term financing notes in 2020
Shanghai Pharmaceutical: Group Co., Ltd.'s announcement on the payment of interest on the third instalment of ultra-short-term financing notes in 2020
Shanghai Pharmaceutical: Announcement on the results of interest payments for the second instalment of ultra-short-term financing notes and the issuance of the third instalment of ultra-short-term financing notes in 2020
Shanghai Pharmaceutical: Announcement on plans to publicly issue corporate bonds
Shanghai Pharmaceutical: Announcement on the results of issuing the first instalment of ultra-short-term financing notes in 2020
Shanghai Pharmaceutical: Announcement on the approval of registration of the company's ultra-short-term financing notes
Shanghai Pharmaceutical: Public Issuance of 2018 Corporate Bonds (Phase I) 2019 Interest Payment Announcement
Shanghai Pharmaceutical: 2018 Corporate Bond Fiduciary Management Report (2018)
Shanghai Pharmaceutical: Announcement on 2018 Corporate Bonds (Phase I) (for Qualified Investors) Tracking Rating Results
Shanghai Pharmaceutical: Announcement on Proposed Issuance of Debt Financing Products
Shanghai Pharmaceutical: Public Offering of 2016 Corporate Bonds (Phase I) Principal and Delisting Notice
Shanghai Pharmaceutical: Announcement on the results of the public issuance of 2018 corporate bonds (for qualified investors) (Phase I)
Shanghai Pharmaceutical: Public Offering of 2018 Corporate Bonds (Phase I) Coupon Interest Rate Announcement
Shanghai Pharmaceutical: Announcement on the application for the public issuance of corporate bonds to qualified investors approved and approved by the China Securities Regulatory Commission
Shanghai Pharmaceutical: Progress announcement on the further acquisition of 26.34% of Guangdong Tianpu Biochemical Co., Ltd.
Shanghai Pharmaceutical: Public Issuance of 2016 Corporate Bonds (Phase I) Fiduciary Management Report (2017)
Shanghai Pharmaceutical: Public Issuance of 2016 Corporate Bonds (Phase I) Follow-up Rating Report (2018)
Shanghai Pharmaceutical: Announcement on 2016 Corporate Bonds (Phase I) Tracking Rating Results
Analysis
Price Target
No Data
